Elsevier BV

SHERPA: Unknown

People

  1. Carlo
    Carlo
  2. Feldman
    Feldman
  3. Kotecha
    Kotecha
  4. Motzer
    Motzer
  5. Schoenfeld
    Schoenfeld
  6. Shah
    Shah
  7. Voss
    Voss
  8. Aggen
    Aggen
  9. Apollo
    Apollo
  10. Arfe
    Arfe

Groups

  1. Department of Medicine (6)
  2. Hematologic Malignancies, Division of (6)
  3. Solid Tumor Oncology Division (5)
  4. Epidemiology and Biostatistics (4)
  5. Weinberg Fellows (4)
  6. Biostatistics Service (3)
  7. Department of Pathology and Laboratory Medicine (3)
  8. GSK Faculty (3)
  9. Genitourinary Oncology Service (3)
  10. Graduate Medical Education (3)
Search Within
  1. "Hematologic Malignancies, Division of"
Formats
  1. Journal Article (5)
  2. Editorial (1)
Groups
  1. Department of Medicine (6)
  2. Hematologic Malignancies, Division of (6)
  3. Solid Tumor Oncology Division (5)
  4. Epidemiology and Biostatistics (4)
  5. Weinberg Fellows (4)
  6. Biostatistics Service (3)

More Groups

People
  1. Adam Schoenfeld (2)
  2. Chung-Han Lee (2)
  3. Darren Feldman (2)
  4. Maria Carlo (2)
  5. Martin Voss (2)
  6. Neil Shah (2)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2021 (2)
Publications
  1. European Urology Oncology (2)
  2. JTO Clinical and Research Reports (2)
  3. European Journal of Internal Medicine (1)
  4. European Urology Open Science (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brief report: Clinical characteristics and outcomes of patients with thoracic SMARCA4-deficient undifferentiated tumors
    Journal Article

    Cooper, A. J.; Arfe, A.; Ricciuti, B.; Gagné, A.; Sholl, L. M.; Di Federico, A.; Awad, M. M.; Aldea, M.; Ghigna, M. R.; Grecea, M.; more...
    JTO Clinical and Research Reports (2025)

    Fulltext@MSK | Save
  • Realizing the scope of venous and arterial thrombosis in cyclin-dependent kinase 4/6 inhibitors in hormone positive breast cancer
    Editorial

    Wilkins, C. R.; Zwicker, J. I.
    European Journal of Internal Medicine (2024)

    Fulltext@MSK | Save
  • Three-year overall survival outcomes and correlative analyses in patients with NSCLC and high (50%–89%) versus very high (≥90%) programmed death-ligand 1 expression treated with first-line pembrolizumab or cemiplimab
    Journal Article

    Ricciuti, B.; Elkrief, A.; Lin, J.; Zhang, J.; Alessi, J. V.; Lamberti, G.; Gandhi, M.; Di Federico, A.; Pecci, F.; Wang, X.; more...
    JTO Clinical and Research Reports (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of talazoparib and avelumab in genomically defined metastatic kidney cancer
    Journal Article

    Kotecha, R. R.; Doshi, S. D.; Knezevic, A.; Chaim, J.; Chen, Y.; Jacobi, R.; Zucker, M.; Reznik, E.; McHugh, D.; Shah, N. J.; more...
    European Urology Oncology (2024)

    Fulltext@MSK | Save
  • Germline variants identified in patients with early-onset renal cell carcinoma referred for germline genetic testing
    Journal Article

    Truong, H.; Sheikh, R.; Kotecha, R.; Kemel, Y.; Reisz, P. A.; Lenis, A. T.; Mehta, N. N.; Khurram, A.; Joseph, V.; Mandelker, D.; more...
    European Urology Oncology (2021)

    Fulltext@MSK | Save
  • Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy
    Journal Article

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
    European Urology Open Science (2021)

    Fulltext@MSK | Save

    • Elsevier BV – authorized name for: